Navigation Links
QuoNova Global Executive Appointments

MELBOURNE, Australia, March 17 /PRNewswire/ --

- New Executives Appointed in Senior, Global Roles

- QuoNova Accelerating Compound Development Towards Commercialization

QuoNova LLC, which is developing multiple classes of safe and efficacious anti-virulence agents in the global fight against bacterial infection and damage caused by microbial biofilms, has appointed three new senior executives in global roles to support its next phase of growth.

QuoNova's is developing and commercializing its proprietary Quorum Sensing Blocker ("QSB") platform as part of a strategy to introduce a disruptive paradigm of "smart microbial control". QuoNova, which is 88.7% owned by XL TechGroup, Inc. (AIM: XLT), is targeting multiple multi-billion dollar markets including therapeutics, medical devices, consumer care, agriculture and several industrial applications.

Michael Rochelle has joined QuoNova as VP Strategic Marketing & Business Development. He has over 20 years of commercial experience in biopharmaceuticals, clinical laboratory and consulting. Most recently, Michael was Vice President at Nabi Pharmaceuticals, serving in a variety of roles including strategic planning and business development. He led the acquisition at Nabi of the product PhosLo(R) from Braintree Laboratories, a $100 million deal. Michael's background includes business development roles with International Clinical Laboratories, SmithKline Beecham Laboratories and Integrated Genetics/Genzyme Corporation. He has a BA in Chemistry from Assumption College in Worcester, Massachusetts and an MBA from Bryant University, in Smithfield, Rhode Island.

Jim Walls is the new VP Product Development for QuoNova. He has over 25 years of medical device product development experience, 15 years of which were dedicated to reducing hospital acquired medical device infections. He has held VP of R&D positions for Kendall Healthcare (now Covidien, LLC) and C.R. Bard, Inc. Most recently he was VP of Business Development for Bacterin International, Inc. Jim holds a BS in Mechanical Engineering from the University of Connecticut, an MS in Biomedical Engineering from Rensselaer Polytechnic Institute, and has completed a Clinical Engineering Internship at Hartford Hospital. He has also completed courses towards his MBA at the University of New Haven.

Mohamed Baccouche has joined as VP Regulatory Affairs and is based in QuoNova's office in Germany. He has 30 years experience in the pharmaceutical industry with clinical development, project management and regulatory strategy for new drugs and maintenance of worldwide marketed products. Most recently, he was head of Global Regulatory Affairs and Scientific Information at Byk Gulden and Altana Pharma. Mohamed holds an MS in Chemistry and a Ph.D in Organic Chemistry from the University of Braunschweig, Germany.

QuoNova's QSB technology is an anti-virulence approach, which shows potential to prevent the consequences of microbial infection while not promoting resistance. In recent months, QuoNova has demonstrated the efficacy of its QSB technology in a predictive animal model where QSBs significantly reduced the ability of clinically relevant bacteria to colonize secondary burn wounds. In addition, a marked synergy with Silver Sulfadiazine, a commonly used antibacterial preparation, has been observed. QuoNova has also generated in-vitro data indicating high efficacy of selected QSBs in inhibiting biofilm formation by MRSA (methicillin-resistant Staphylococcus aureus) strains and fungal organisms such as Candida.

Dr. Heiri Gugger, CEO of QuoNova, said: "The excellent progress continuing to be made by our scientific team in identifying, optimizing and testing our compounds across a broad spectrum gives us even greater confidence in our QSB platform to rapidly move towards targeted development and commercialization. I am therefore delighted that we have been able to attract top industry talent with years of relevant experience, which is a testament to our progress and further validates the growth potential of QuoNova.

Notes to Editors

About QuoNova LLC

QuoNova was founded in December 2006 and is the fifth portfolio company of XL TechGroup. QuoNova develops safe and efficacious anti-virulence agents in the global fight against infection and damage caused by microbial biofilms. QuoNova's business strategy is to develop and commercialize its proprietary Quorum Sensing Blocker ("QSB") platform and introduce a disruptive paradigm of "smart microbial control". QuoNova is targeting multiple multi-billion dollar markets including therapeutics, medical devices, consumer care, agriculture and several industrial applications.

Micro-organisms use chemical signal molecules to communicate and recognize population density (Quorum Sensing) in order to organize their social behaviour, and co-ordinate the production of virulence factors, such as the release of toxins and biofilm formation. Biofilms are complex matrices produced by colonies of micro-organisms, and are very difficult to eradicate as they protect themselves against the immune system or conventional treatments such as antibiotics or biocides. In the healthcare environment they contribute significantly to complications in lung disease and wound healing, to medical device-associated infections as well as to dental plaque and contact lens-associated infection. In the home and in industrial processes they are a major cause of contamination, corrosion and efficiency reductions.

QuoNova's QSB technology disrupts microbial communication systems and by so doing inhibits toxin production, prevents biofilm formation and promotes degradation of already established biofilms. Moreover, research to date indicates that QuoNova's QSB compounds have a favourable safety profile. QSB molecules employ an anti-virulence approach and do not kill micro-organisms, but instead influence their life style to maintain or return them to a state where they can be removed by intrinsic control mechanisms such as the immune system or by treatments much less aggressive than those currently available. This should significantly reduce or eliminate the processes that lead to the development of drug resistant organisms, and differentiates QSBs substantially from conventional antimicrobial approaches. QSB molecules will therefore initiate a new era in preventing the effects of microbial colonization, capable of overcoming the decreasing effectiveness of conventional treatments against biofilms and multi-resistant pathogens.
For further information, see

For further information:


Dr. Heiri Gugger, CEO QuoNova LLC Tel: +1-321-409-7411

Dr. Jonathan Turner, MD QuoNova Europe GmbH Tel: +49-611-580-7856

QuoNova media enquiries:

Abchurch Communications

Heather Salmond Tel: +44(0)20-7398-7704

Gareth Mead Tel: +44(0)20-7398-7710

Main: +44(0)20-7398-7700

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
2. Quest Diagnostics to Speak at Lehman Brothers 11th Annual Global Healthcare Conference
3. deCODE genetics to Webcast Presentation at Lehman Brothers Eleventh Annual Global Healthcare Conference
4. Wyeth to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
5. NuVasive to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference
6. MiddleBrook Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference
7. Genomic Health to Present at Lehman Brothers Global Healthcare Conference
8. PAREXEL International to Present at Lehman Brothers 11th Annual Global Healthcare Conference
9. The Bill & Melinda Gates Foundation, BIO, and Bio Ventures for Global Health Invite Proteome Systems CEO to Speak on TB Diagnostics Solutions At Partnering for Global Health Forum, Washington D.C.
10. Baxter and Its Foundation Contribute Nearly $53 Million in 2007 to Address Critical Needs Locally and Globally
11. Vical to Present at BIO and BVGH Global Health Partnering Event
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... 23, 2016 Andrew ... Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
(Date:6/23/2016)... San Francisco, CA (PRWEB) , ... June 23, ... ... capture (EDC) software, is exhibiting at the Pennsylvania Convention Center and will showcase ... DIA Annual conference. ClinCapture will also be presenting a scientific poster on Disrupting ...
(Date:6/23/2016)... Connecticut (PRWEB) , ... June 23, 2016 , ... ... introduce a new line of intelligent tools designed, tuned and optimized exclusively for ... September 12–17 in Chicago. The result of a collaboration among several companies with ...
Breaking Biology Technology:
(Date:5/12/2016)... -- , a brand of Troubadour Research ... the Q1 wave of its quarterly wearables survey. A ... to a program where they would receive discounts for ... "We were surprised to see that so ... , CEO of Troubadour Research, "primarily because there are ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
Breaking Biology News(10 mins):